Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma

Andrew Li¹,², Hiang Ping Chan¹,², Phyllis X.L. Gan³,⁴, Mei Fong Liew¹,⁵, W.S. Fred Wong³,⁴, and Hui-Fang Lim¹,²

Approximately 25% to 40% of patients with chronic obstructive pulmonary disease (COPD) have the eosinophilic endotype. It is important to identify this group accurately because they are more symptomatic and are at increased risk for exacerbations and accelerated decline in forced expiratory volume in the 1st second. Importantly, this endotype is a marker of treatment responsiveness to inhaled corticosteroid (ICS), resulting in decreased mortality risk. In this review, we highlight differences in the biology of eosinophils in COPD compared to asthma and the different definitions of the COPD eosinophilic endotype based on sputum and blood eosinophil count (BEC) with the corresponding limitations. Although BEC is useful as a biomarker for eosinophilic COPD endotype, optimal BEC cutoffs can be combined with clinical characteristics to improve its sensitivity and specificity. A targeted approach comprising airway eosinophilia and appropriate clinical and physiological features may improve identification of subgroups of patients who would benefit from biologic therapy or early use of ICS for disease modification.

Keywords: Pulmonary disease, chronic obstructive; Inhaled corticosteroids; Eosinophilia

INTRODUCTION

The prevalence of chronic obstructive pulmonary disease (COPD) is 11% to 26%, higher than that of asthma [1,2]. This worrisome trend is expected to continue over the next 25 years [2]. COPD is responsible for 2.6% of the global disability adjusted life years [3] and is projected to be the third leading cause of death worldwide in 2030 [4].
Recurrent exacerbations in COPD are associated with an accelerated decline in physical function and forced expiratory volume in the 1st second (FEV₁), and a high economic burden [5-7]. The 30-day COPD readmission rate is 15% to 30% [8]. Approximately 30% of all COPD exacerbations are life-threatening, requiring mechanical ventilation. After hospital discharge, the readmission rate stagnates at 20% with a 90-day mortality rate of up to 20% [9].

Because recurrent COPD exacerbation is a poor prognostic indicator, guidelines are increasingly recognizing the importance of accurately identifying risk factors in individual patients to reduce the disease burden [10]. However, risk prediction using clinical characteristics, such as a history of prior exacerbation, cannot identify the underlying pathobiological mechanisms [7]. This often results in empirical treatment and suboptimal treatment outcomes. Hence, in the last 8 years, there has been increased awareness of COPD as a heterogeneous disease with different endotypes, similar to asthma [11,12].

Although COPD is typically characterized by neutrophilic inflammation, the eosinophilic endotype is not rare. Approximately 25% to 40% of patients with COPD have eosinophilic airway [13], and 28% of acute exacerbations in COPD are associated with airway eosinophilia [14]. Uncontrolled airway eosinophilia gives rise to recurrent exacerbations and hospitalizations [15,16]. As such, the COPD eosinophilic endotype is an important subgroup to identify and target because though it is associated with an increased risk of exacerbations, the risk is mitigated by inhaled corticosteroid (ICS) [17]. However, the response to ICS and anti-eosinophilic agents among eosinophilic COPD patients is mixed and different from asthma [18-20]. In this review, we discuss the role of eosinophil in COPD compared to asthma, the definitions of the COPD eosinophilic endotype and the corresponding limitations.

**THE BIOLOGY OF EOSINOPHILS IN THE AIRWAYS**

Eosinophils are recognized by their distinctive bilobed nuclei and protein-filled granules. Under the influence of cytokines such as granulocyte-monocyte colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5, eosinophils differentiate and mature from hematopoietic stem cells in the bone marrow (Fig. 1). Thereafter, eosinophils infiltrate the lung tissue via the bloodstream [2]. Eosinophil transmigration from the blood into the lungs prolongs the eosinophil half-life from hours to days, especially in the presence of mediators such as GM-CSF, IL-3, IL-25, IL-33, and thymic stromal lymphopoietin during airway inflammation [21,22]. Eosinophils release a wide array of cytokines, chemokines, and proteins that cause mucus hypersecretion from goblet cells, airway remodeling, and airway hyperreactivity [23]. Four major proteins mediate eosinophil’s toxic effects in the airways: major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil derived neurotoxin [2]. MBP and EPO induce airway hyperreactivity by stimulating histamine secretion from mast cells and basophils [23,24]. MBP and ECP can trigger excessive damage-repair pathway activation in the respiratory epithelium, contributing to airway remodeling [23-25]. This can be augmented by the release of matrix metalloproteinase (MMP)-9 and transforming growth factor-β by eosinophils to recruit and activate neighboring fibroblasts [23,25]. In addition, eosinophils promote goblet cell differentiation and mucus hypersecretion by releasing IL-13 [25,26]. Together, these factors drive the hallmarks of an eosinophilic exacerbation with increased sputum production and bronchoconstriction.

Eosinophil functions are highly regulated by its cell surface receptors, including IL-5 receptor (IL-5R), sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8), and CC-chemokine receptor 3 (CCR3), which control its differentiation, migration, and survival [23,24]. Other receptors include toll-like receptor (TLR) 3, 7, 8, and 9, which promote viral asthma exacerbations, whereas TLR 2/6 heterodimer facilitates clearance of respiratory syncytial virus [27,28]. Among these receptors, IL-5R is the major player in eosinophil maturation, activation, and survival [29,30].

This has led to the introduction of anti-IL-5 biologic therapies specifically targeted at reducing eosinophilic asthma exacerbations [31-36]. However, blockade of the IL-5 pathway alone is insufficient for controlling asthma exacerbations [29,37], suggesting that eosinophil activity is dependent on multiple receptor networks, and highlighting the complexity of eosinophil biology. Further-
more, preferential expression of major histocompatibility complex class II (MHC-II) on activated eosinophils in the presence of GM-CSF and IL-4 suggests that eosinophils play a role in antigen presentation and B-cell activation [27,38].

**MECHANISTIC EFFECT OF EOSINOPHIL IN COPD VERSUS ASTHMA**

The mechanism behind eosinophilic COPD is distinct from eosinophilic asthma. The activation of eosinophils by IL-33, rather than IL-5, correlates with the increase in IL-13 levels in COPD, promoting emphysematous MMP-12 release by macrophages [39]. This suggests an indirect mechanism in which eosinophils induce airway remodeling in COPD. Moreover, although the release of MBP is highly associated with eosinophilic asthma, COPD exacerbation has been linked to higher ECP levels [23,24,40].

In parallel with their destructive role, eosinophils could also promote resolution of inflammation by secreting pro-resolving lipid mediators such as resolvin E3 and protectin D1 and recruiting alternatively activated macrophages [41]. The overall action of eosinophils in inflammation involves the fine coordination of a complex network of mediators and surface receptors. It has been postulated that eosinophil functions in asthma are regulated by dendritic cells and T helper 2 (Th2) cells, whereas eosinophil functions in COPD are coordinated by type 2 innate lymphoid cells (ILC2) [2].

**BIOMARKERS OF THE EOSINOPHILIC ENDTYPE OF COPD**

**Sputum cell count quantification**

Sputum eosinophilia > 3% is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard of airway eosinophilia in asthma and COPD [42-44]. In asthma, sputum eosinophil counts can more reliably guide physicians to tailor ICS treatment to prevent exacerbations, compared to other markers [45]. It has also been used as a biomarker of severe eosinophilic asthma patients in the phase 2 mepolizumab studies [31].

The application of airway endotyping among COPD patients has gained traction only in the last few years, despite its introduction in the 1990s [43,46,47]. An analysis of the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) cohort of 2,499 COPD patients further validated the clinical utility of sputum eosinophilia identification in this population, and greater sputum eosinophilia highlighted a subgroup of patients with more severe disease (i.e., lower predicted FEV1), more frequent exacerbations, and increased emphysema on quantitative computed tomography scan when compared to blood eosinophilia [48].

However, sputum cell count quantification is mainly available in airway research centers [49]. Several obstacles prevent its use in mainstream airway assessment: sputum induction yields an adequate yield only 70% of the time and can result in significant bronchospasm in patients with baseline low FEV1 [50,51], the sputum samples must be processed within 2 hours [49], and the sputum processing and cell-count quantification methods are manual and comparatively labor-intensive [49]. Although the repeatability of sputum eosinophilia is moderate (intraclass coefficient [ICC] 0.63) in the short-term (i.e., 2 weeks) and weak (ICC 0.49) in the medium- to long-term (i.e., 12 weeks) [52,53], this might reflect ongoing changes in the airway immune responses as a result of environmental triggers.

**Blood eosinophil count**

Blood eosinophil count (BEC) is an easily measured surrogate of airway eosinophilia. A high BEC is associated with higher sputum and BAL eosinophil counts and IL-5 level, and greater tissue remodelling [54]. BEC has reasonable specificity and sensitivity for predicting airway eosinophilia (Table 1) [17,55,56]. However, there are several limitations to using BEC as a predictor of airway eosinophilia and a biomarker of corticosteroid and biologic therapy responsiveness.

BEC cut-offs in the various studies have been arbitrary, with no over-arching consensus. Some studies have defined airway eosinophilia based on the population of eosinophils as a percentage of the total leukocyte count [57,58] whereas others have focused on an absolute BEC of 150 to 300 cells/µL [59-64]. Cut-off values relying on percentages are less reliable [65], giving rise to interpretation ambiguity. As such, the ideal cut-off is unknown and depends on individual patient characteristics and
The clinical context [55,56,66]. A higher specificity is preferred to rule-in a patient with a true eosinophilic endotype, particularly among patients with COPD already on maintenance ICS who are ex-smokers [67], but such cut-offs require further validation.

Although a high BEC is associated with increased risk for exacerbations, up to 50% of patients with a single high BEC are not frequent exacerbators [13]. The timing of the BEC matters. BEC levels do fluctuate throughout the COPD course, which is also affected by age, gender, and illness phase (at baseline or during exacerbation) [68,69]. However, most studies have relied on baseline BEC levels to determine the status of airway eosinophilia, which may not be a true reflection of the actual airway inflammatory status [57-64]. This may lead to occasional contrary results on the influence of ICS among patients with higher BEC levels [59].

In fact, BEC levels poorly correlate with sputum eosinophilia [48]. Although a ≥ 3% sputum eosinophil count at baseline is associated with an increased risk for eosinophilic-driven acute COPD exacerbation (odds ratio, 2.7; p = 0.01) [14], the converse is not true of a high BEC in a stable state. A 2% BEC cut-off, used to identify sputum eosinophilia ≥ 3%, has a high sensitivity of 90% and a low specificity of 60%, indicating that the BEC cut-off is more useful as a rule-in rather than a confirmatory bio-

Table 1. Studies of the accuracy of blood eosinophilia counts for predicting sputum eosinophilia > 3%

| Study                | Design                        | Current smoker, % | Baseline medications | BEC thresholds | Sensitivity, % | Specificity, % |
|----------------------|-------------------------------|-------------------|----------------------|----------------|---------------|---------------|
| Bafadhel et al. [17] | Longitudinal study, exacerbation state | 31                | ICS: 86% LABA: 76%   | 2%             | 90            | 60            |
| Schleich et al. [55] | Retrospective, stable state   | 43                | ICS: 61% LABA: 75%   | 162 cells/µL   | 71            | 67            |
|                      |                               |                   |                       | 2.6%           | 53            | 83            |
|                      | Subgroup on high dose ICS (n = 50) |                   |                       | 215 cells/µL   | 60            | 93            |
| Negewo et al. [56]   | Cross-sectional, stable state | 18.7              | ICS or ICS-LABA: 90.8% | 200 cells/µL  | 91.1          | 50            |
|                      |                               |                   |                       | 300 cells/µL   | 60            | 76            |
|                      |                               |                   |                       | 400 cells/µL   | 31.1          | 91.7          |

BEC, blood eosinophil count; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting anti-muscarinic antagonist.

Table 1. Studies of the accuracy of blood eosinophilia counts for predicting sputum eosinophilia > 3%

The fractional exhaled nitric oxide

Although fractional exhaled nitric oxide (FeNO) has been proposed to guide ICS use among asthma patients, it is not a reliable surrogate marker of airway eosinophilia [45]. FeNO is mediated by IL-13 and IL-4 rather than IL-5, which may explain the minimal impact of mepolizumab, an anti-IL-5 biologic agent, on FeNO levels [31]. Several small studies have demonstrated a positive correlation among FeNO, sputum eosinophils [70], and BEC levels [71] during COPD exacerbations. However, the diagnosis of the COPD eosinophilic endotype should not be made during an exacerbation, but rather when the patient is stable. Schleich et al. [55] showed that, compared to BEC levels, FeNO had a weaker correlation with sputum eo-

Fractional exhaled nitric oxide

Although fractional exhaled nitric oxide (FeNO) has been proposed to guide ICS use among asthma patients, it is not a reliable surrogate marker of airway eosinophilia [45]. FeNO is mediated by IL-13 and IL-4 rather than IL-5, which may explain the minimal impact of mepolizumab, an anti-IL-5 biologic agent, on FeNO levels [31]. Several small studies have demonstrated a positive correlation among FeNO, sputum eosinophils [70], and BEC levels [71] during COPD exacerbations. However, the diagnosis of the COPD eosinophilic endotype should not be made during an exacerbation, but rather when the patient is stable. Schleich et al. [55] showed that, compared to BEC levels, FeNO had a weaker correlation with sputum eo-
Table 2. Prospective studies of the effects of withdrawing inhaled corticosteroids among patients with COPD and eosinophilia

| Study                  | Study population                                      | Study conduct                                                                 | Outcomes                                                                 |
|------------------------|-------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Watz et al. [63]       | GOLD 3/4 COPD (FEV\(_1\) < 50% predicted, FVC < 70% predicted), > 40 years old ≥ 1 Exacerbation in the last year | Run-in period of tiotropium + salmeterol + fluticasone for 6 weeks          | Subgroup analyses                                                       |
|                        |                                                       | Randomized to either for 12 months                                           |                                                                          |
|                        |                                                       | Continue tiotropium + salmeterol + fluticasone placebo (n = 1,244)           |                                                                          |
|                        |                                                       | Tiotropium + salmeterol.                                                     |                                                                          |
|                        |                                                       | Gradual withdrawal of fluticasone in 12 weeks (n = 1,244)                   |                                                                          |
|                        |                                                       |                                                                              | Absolute BEC (cells/μL)                                                   |
|                        |                                                       |                                                                              | Patients with BEC ≥ 4%                                                   |
|                        |                                                       |                                                                              | Increased risk of moderate/severe exacerbations with ICS withdrawal compared to those < 4% |
|                        |                                                       |                                                                              | Shorter time to first moderate/severe exacerbation with ICS withdrawal compared to those < 4% |
|                        |                                                       |                                                                              | Decreased trough FEV\(_1\), with ICS withdrawal compared to those < 4%    |
|                        |                                                       |                                                                              | Patients with BEC ≥ 5%                                                   |
|                        |                                                       |                                                                              | Increased risk of severe exacerbations with ICS withdrawal compared to those < 5% |
| Chapman et al. [64]   | COPD (FEV\(_1\), 40%–80% predicted), > 40 years old On triple therapy for at least 6/12 prior to enrollment ≤ 1 exacerbation in the last year | Run-in period of tiotropium + salmeterol/fluticasone for 30 days           | Subgroup analyses                                                       |
|                        |                                                       | Randomized to either for 26 weeks                                           |                                                                          |
|                        |                                                       | Indacaterol/ glycopyrronium + tiotropium and salmeterol/fluticasone placebo (n = 527) |                                                                          |
|                        |                                                       | Tiotropium and salmeterol/fluticasone + indacaterol/ glycopyrronium placebo (n = 526) |                                                                          |
|                        |                                                       |                                                                              | Absolute BEC (cells/μL)                                                   |
|                        |                                                       |                                                                              | Patients with BEC ≥ 300                                                  |
|                        |                                                       |                                                                              | Increased risk of moderate/severe exacerbations with ICS withdrawal compared to those < 300 |
|                        |                                                       |                                                                              | Shorter time to first exacerbation with ICS withdrawal compared to those < 300 |
|                        |                                                       |                                                                              | Decreased trough FEV\(_1\), with ICS withdrawal compared to those < 300    |

COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV\(_1\), forced expiratory volume in the 1st second; FVC, forced vital capacity; BEC, blood eosinophil count; ICS, inhaled corticosteroid.
Table 3. Prospective studies of the effect of adding inhaled corticosteroids to the treatment regimen among patients with COPD and only eosinophilia

| Study | COPD study population | Study conduct | Exacerbation rate | Symptoms | Trough FEV₁ |
|-------|-----------------------|---------------|-------------------|----------|-------------|
| TRILOGY [59] | FEV₁ < 50% predicted ≥ 1 moderate/severe exacerbation in the previous year Symptomatic (CAT ≥ 10) despite using LAMA, LAMA/LABA, LAMA/steroid or LABA/steroid for > 2 months prior to screening | 2-Week run-in of formoterol fumarate/beclametasone dipropionate, followed by randomization to one of the groups for 52 weeks Fixed triple therapy of beclomethasone dipropionate/formoterol fumarate/glycopyrronium (n = 687) Beclomethasone dipropionate/formoterol fumarate (n = 681) | Reduction of exacerbation rates in favour of triple therapy, but no association with BEC | Greater symptomatic improvement in terms of increased TDI focal score, but no association with BEC | Greater mean difference in pre-dose FEV₁ and 20-hour post-dose FEV₁, but no association with BEC |
| KRONOS [60] | FEV₁ 25%–80% predicted Symptomatic (CAT ≥ 10) despite 2 inhalers ≥ 6 weeks before screening | Run-in period of only ipratropium and ICS (If present ≥ 4 weeks prior to screening), followed by randomization to one of the groups for 24 weeks Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) (n = 640) Glycopyrronium/formoterol fumarate (GFF) (n = 627) Budesonide/formoterol fumarate (BFF) (n = 316) “Open-label” budesonide/formoterol fumarate (BFF′) (n = 319) | Reduction of moderate/severe exacerbations for BGF relative to GFF with increasing eosinophil concentrations, starting at 75–100 cells/mm³ | Greater symptomatic improvement in terms of SGRQ (favoring BGF compared to GFF) and TDI focal score (favoring BGF compared to GFF and BFF) changes, but no comment about impact of BEC | Improvements in change from baseline for BGF relative to GFF if > 150 cells/mm³ Improvements over 24 weeks for BGF relative to GFF if > 250 cells/mm³ No eosinophil cut-off for improvement between BGF and BFF |
| TRINITY [57] | FEV₁ < 50% predicted ≥ 1 moderate/severe exacerbation in the previous year Symptomatic (CAT ≥ 10) despite using LAMA, LAMA/LABA, LAMA/steroid or LABA/steroid for > 2 months prior to screening | 2-Week run-in of only tiotropium, followed by randomization to one of the groups for 52 weeks Fixed triple therapy of beclomethasone dipropionate/formoterol fumarate/glycopyrronium (n = 1,078) Open-label of beclomethasone dipropionate/formoterol fumarate/glycopyrronium (n = 538) Tiotropium (n = 1,075) | Reduction of exacerbation rates greater among those with BEC > 200 cells/μL and ≥ 2%, in favor of triple therapy (fixed and open) | Greater symptomatic improvement in terms of SGRQ total score change, but no comment about impact of BEC | Consistently greater mean changes from baseline in pre-dose FEV₁ at 52 weeks in favour of triple therapy, but not affected by BEC |
| Study   | COPD study population | Study conduct | Exacerbation rate |
|---------|-----------------------|---------------|------------------|
| TRIBUTE [58] | FEV₁ < 50% predicted ≥ 1 moderate/severe exacerbation in the previous year | 2-Week run-in of indacaterol/glycopyrronium, followed by randomization to one of the groups for 52 weeks | Exacerbation rates decreased in favour of triple therapy among those with BEC ≥ 200 cells/µL and ≥ 2% |
|          | Symptomatic (CAT ≥ 10) despite using LAMA, LAMA/LABA, LAMA/steroid or LABA/steroid for > 2 months prior to screening | Fixed triple therapy of beclometasone dipropionate/formoterol fumarate/glycopyrronium (n = 764) Indacaterol/glycopyrronium (n = 768) | Greater symptomatic improvement in terms of SGRQ total score change, but no comment about impact of BEC |
| IMPACT [61] | FEV₁ < 50% predicted + ≥ 1 moderate/severe exacerbation in the previous year FEV₁ 50%–80% predicted + ≥ 2 moderate or ≥ 1 severe exacerbation in the previous year Symptomatic (CAT ≥ 10) | 2-Week run-in of their own medications, followed by randomization to one of the groups for 52 weeks | Greater reduction in moderate/severe exacerbation rates in favor of triple therapy and Breo, compared to Anoro among those with BEC ≥ 100 cells/µL |
|          |                      | Fixed triple therapy of fluticasone furoate/umeclidinium/vilanterol (n = 4,143) Fluticasone furoate/vilanterol (Breo) (n = 4,125) Umeclidinium/vilanterol (Anoro) (n = 2,065) | Exacerbation rates in Anoro group increased with increasing BEC Exacerbation rates did not differ with increasing BEC among ICS-containing treatment groups |
| ETHOS [62] | FEV₁ < 50% predicted + ≥ 1 moderate/severe exacerbation in the previous year FEV₁ 50%–80% predicted + ≥ 2 moderate or ≥ 1 severe exacerbation in the previous year Symptomatic (CAT ≥ 10) despite 2 inhaled maintenance therapies | 4-Week run-in of only ICS, followed by randomization into the following groups for 52 weeks | Greater reduction in annual rate of moderate/severe exacerbation in favour of ICS-containing therapies among those with BEC ≥ 150 cells/µL |
|          |                      | Fixed triple therapy of 320 µg budesonide/glycopyrrrolate/formoterol fumarate (n = 2,157) Fixed triple therapy of 160 µg budesonide/glycopyrrrolate/formoterol fumarate (n = 2,137) Glycopyrrrolate/formoterol fumarate (n = 2,143) Budesonide/formoterol fumarate (n = 2,151) | Greater symptomatic improvement based on SGRQ total score and TDI focal score changes were greater in favour of ICS-containing therapies among those with higher baseline BEC |

COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in the 1st second; CAT, COPD assessment test; LAMA, long-acting anti-muscarinic antagonist; LABA, long-acting beta-agonist; BEC, blood eosinophil count; TDI, transient dyspnea index; ICS, inhaled corticosteroid; SGRQ, St George’s respiratory questionnaire.
sinophils at steady state. As such, FeNO is not used to define the COPD eosinophilic endotype.

EOSINOPHILIC COPD: CLINICAL IMPLICATIONS

Higher BEC among COPD patients is associated with a lower FEV₁, greater bronchodilator reversibility, and larger differences between baseline and post-bronchodilator FEV₁ [15,48]. The ECLIPSE (Evaluation of COPD to longitudinally identify predictive surrogate endpoints) study had contrasting findings but focused on neutrophilic rather than eosinophilic airway inflammation [13]. These significant differences in FEV₁ are unlikely to be clinically significant. More importantly, the rate of FEV₁ decline is accelerated among those with airway eosinophilia [72], necessitating early intervention. COPD patients with higher BEC tend to be more symptomatic, with quicker progression of emphysema and air trapping [48].

These patients are generally at increased risk of recurrent exacerbations [15,16]. Up to 28% of acute COPD exacerbations are associated with airway eosinophilia [14]. This has been observed in many prospective studies, of which the largest was the Copenhagen General Population study, where 7,225 COPD patients were followed up for a median of 3.3 years. Those who had elevated BEC (i.e., >345 cells/µL) were at increased risk for moderate and severe exacerbations [15]. Nonetheless, these patients respond favorably to ICS with fewer treatment failures [67], have a shorter median hospital stay [73],

Figure 1. The biology of eosinophilic airway inflammation. T2-high inflammation (eosinophilic) can be allergic or non-allergic. Allergens trigger the production of interleukin 4 (IL-4) and a cascade of T2-high inflammation, leading to specific immunoglobulin E (sIgE) production by activated B cells and mast cell degranulation. Non-allergic T2-high inflammation relies on IL-5 and IL-13 by type 2 innate lymphoid cell (ILC2) and T helper type 2 cell (Th2) cells. Both allergic and non-allergic T2-high inflammation lead to bronchial smooth muscle hypertrophy and goblet cell metaplasia, which cause bronchospasm, mucous hypersecretion and airway remodelling in chronic asthma. TSLP, thymic stromal lymphopoietin; ECP, eosinophil cationic protein; MBP, major basic protein; EPO, eosinophil peroxidase; EDN, eosinophil derived neurotoxin; MMP, matrix metalloproteinase.
and are associated with decreased mortality [74,75]. Recent reports on ICS addition and withdrawal reaffirmed these findings among the subset of COPD patients with airway eosinophilia (Tables 2 and 3) [57-64]. Importantly, higher BEC attenuates the pneumonia risk [76,77]. This is biologically plausible because eosinophils have antibacterial properties, and is further supported by the inverse relationship between bacterial infection and BEC in patients with COPD exacerbations [78].

RESPONSES TO ANTI-EOSINOPHILIC TREATMENT IN EOSINOPHILIC COPD VERSUS ASTHMA

Inhaled corticosteroids
Unlike asthma management where ICS has been the mainstay inhaler [42], the GOLD guidelines do not advocate the initiation of ICS as the first-line treatment [79]. Long-acting bronchodilators (LABs) remain the initial inhaler of choice as a first-line therapy given their superior clinical efficacy for COPD patients of lower severity. The post hoc analysis of the FLAME (Effect of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone on COPD exacerbations) study, which compared the efficacy of indacaterol-glycopyrronium and salmeterol-fluticasone among LAB-naïve COPD patients, suggested that dual LABs are more effective, regardless of the BEC [80]. ICS would be initiated only for patients with COPD who remain symptomatic, and are frequent exacerbators with BEC > 300 cells/µL, despite being compliant with dual LAB. This is in line with data from the recent studies of the addition of ICS to dual LAB [57-62].

These recommendations are based on data from post hoc analyses showing that high BEC cut-offs are indicative of the eosinophilic endotype that benefits from ICS treatment, with a modest exacerbation reduction of 30% [17,81]. They are also intended to leverage the risk-benefit relationship between ICS efficacy and pneumonia incidence, given that unnecessary ICS may portend increased risk for severe pneumonia [82]. However, clinicians should be aware that the recommendations are based on the assumption that these patients have recurrent exacerbations due to persistently raised sputum eosinophilia and so the improvement with ICS is secondary to eosinophil reduction [83].

This assumption has been challenged. In one study, a 4-week course of ICS reduced sputum total cell counts but did not improve lung function or reduce the differential eosinophil count or exhaled nitrous oxide [84]. In a meta-analysis, ICS reduced lymphocyte levels in the bronchial wall, and lymphocyte and neutrophil levels in the bronchoalveolar lavage [85]. Interestingly, in another study, high-dose inhaled fluticasone reduced sputum leukocyte density and neutrophilic inflammatory indices (IL-1B, IL-8, and leukotriene B4 [LTB4]) in bronchietasis patients, suggesting an immunomodulatory effect unrelated to eosinophilia [86]. These studies highlight that ICS might have anti-inflammatory benefit in COPD beyond eosinophil depletion, because it reduces the counts of total cells and neutrophils in sputum. However, Bafadhel et al. [87] demonstrated that utilizing BEC to direct oral corticosteroid or antibiotic therapy was as safe as conventional therapy. The benefit was seen even among those with severe exacerbations requiring hospitalization, irrespective of the inflammatory state [88]. Thus, the benefit of corticosteroids is likely pleiotropic in COPD patients and the mechanisms underlying the association between higher BEC levels and the ICS effect are unclear.

The optimal BEC cut-off is unknown. Early studies used sputum eosinophil counts instead of BEC [43]. In those studies, systemic corticosteroids and ICS reduced airway eosinophilia and improved post-bronchodilator FEV₁ and exercise tolerance. Subsequent studies defined eosinophilic COPD based on BEC cut-offs of 2%–4% to 100–300 cells/µL [48,57-64,67,80]. In one study, budesonide-formoterol, compared to formoterol, was associated with an exacerbation reduction (rate ratio, 0.75; 95% confidence interval, 0.57 to 0.99; interaction = 0.015) in patients with COPD and a BEC ≥ 100 cells/µL [17]. In another study, adding fluticasone to vilanterol in eosinophilic patients with COPD with a BEC ≥ 2% resulted in an exacerbation reduction of 29% [81]. However, results have occasionally been contradictory, with BEC levels failing to predict ICS treatment response at cut-offs of 2% and 200 cells/µL in the TRIBUTE (Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease) study [59]. Lower BEC cut-offs tend to be more sensitive rather than specific, thus the population studied may have included milder and even perhaps non-eosinophilic COPD.
patients. For the general COPD population, this may also lead to over- and under-treatment with ICS. Thus, several experts prefer a targeted BERN—on bronchiolitis, eosinophilia, responsiveness to bronchodilator and non-smoking status—approach, based on bronchiolitis, eosinophilia, responsiveness to bronchodilators, and non-smoking status, to select COPD patients for whom ICS might have greater benefit [89]. In this select group, ICS might be a disease modifier and reduce the rate of decline in lung function.

**Anti-interleukin-5 monoclonal antibodies**

BEC levels also failed to predict treatment response to biologic therapy in eosinophilic COPD. This is unexpected given the similarities in clinical and inflammatory features with eosinophilic asthma [31-36]. Several factors could explain these surprising findings. First, the inability of anti-IL-5 agents to control asthma exacerbations suggests greater eosinophil biology complexity [29,37]. Given that we know less about eosinophilic pathobiology in patients with COPD, other mediators could influence the efficacy of biologic therapy. Second, the population studied may not actually truly reflect the target population, namely, patients with eosinophilic COPD. This is best illustrated by the phase 3 studies of mepolizumab and benralizumab, in which BEC cut-offs of 150 and 220 cells/µL, respectively, were used to identify a severe eosinophilic subgroup characterized by frequent exacerbations [19,20]. In a subsequent post hoc analysis, Criner et al. [66] found that the subgroup that responded to benralizumab had an elevated baseline BEC > 300 cells/µL and experienced ≥ 3 exacerbations in the prior 12 months despite triple therapy. These treatment responders also had lower FEV₁ and significant bronchodilator reversibility. This further illustrates the need for a definition of airway eosinophilia.

**ASTHMA-COPD OVERLAP VERSUS COPD EOSINOPHILIC ENDOTYPE**

Asthma-COPD overlap (ACO) remains a controversial disease entity and was removed from the Global Initiative for Asthma reports in 2019. Currently, there is no universally accepted definition of ACO, and there is no international consensus on whether ACO represents a distinct airway entity or is merely a continuum of overlapping airway disease phenotypes and endotypes [90,91]. Given their heterogeneity, ACO patients exhibit multiple permutations of asthma and COPD clinical features, making them difficult to differentiate and characterize on a regular basis. Moreover, the wide spectrum of phenotypes denotes overlapping pathophysiological processes of asthma and COPD to varying degrees [92-94]. Airway eosinophilia features strongly among ACO studies [93-95], contrary to the prior belief that neutrophilic airway inflammation predominates in this subpopulation [90]. In fact, Hile et al. [95] demonstrated that the proportion of ACO patients with airway eosinophilia is higher than that of asthma and COPD patients in a cross-sectional observational study in Australia (55% vs. 44% vs. 29%, respectively).

The eosinophilic COPD endotype had previously been described as an extension of the ACO phenotype spectrum [66], but given the ambiguity of the ACO definition, most studies on eosinophilic COPD have attempted to create a homogenous population by excluding patients with a history of asthma and atopy [57-60,63,64]. However, ACO patients experience worse outcomes than those with asthma and COPD, in terms of a steeper FEV₁ decline, are more symptomatic, and sustain more exacerbations and hospitalizations [96-98]. They are at higher risk for pneumonia, respiratory mortality, and all-cause mortality. This is particularly so among ACO patients with late-onset asthma [98]. It is plausible this could be a result of the high incidence of airway eosinophilia [72]. Hiles et al. [95] showed that the higher incidence of airway eosinophilia among ACO patients is correlated with an increased exacerbation risk compared to patients with eosinophilic COPD. Further studies are required to validate this observation and the lack of a proper ACO definition has impeded progress thus far.

ACO studies have advocated aggressive management of the asthma and COPD components. Long-acting beta agonist/ICS combination therapy has been the first-line treatment, but this recommendation is based on expert opinion rather than actual studies [96]. Although most ICS studies that have focused on eosinophilic COPD did not include patients with ACO [57-60,63,64], the ETHOS (Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD) study included patients with a prior asthma diagnosis [62] and reported a greater
efficacy of ICS among patients with airway eosinophilia (Table 3). This can potentially be extrapolated to patients with ACO and reinforces the need for ICS as the initial therapy of choice.

CONCLUSIONS

Eosinophilic COPD is an airway inflammatory endotype associated with an increased risk for exacerbations and treatment responsiveness to ICS. Although BEC is useful as a biomarker to identify this group, its low concordance with sputum eosinophilia and relatively low specificity can result in over- or under-treatment with ICS. Clinicians should note that the optimal BEC cut-off is dependent on the clinical context (to rule in or rule out an eosinophilic endotype), and must be interpreted together with other clinical characteristics. Importantly, the biological mechanisms of eosinophils might differ between COPD and asthma. ICS might have anti-inflammatory benefit in COPD beyond eosinophil depletion, because it reduces the numbers of total cells and neutrophils in sputum. A targeted approach combining the presence of eosinophilia with other relevant features might promote identification of a subgroup in which ICS functions as a disease modifier.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This work was partly supported by a grant NUHSRO/2020/044/T1/1 to W.S. Fred Wong and Hui-Fang Lim.

REFERENCES

1. Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur Respir J 2019;54:1900610.
2. George I, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 2016;7:34-51.
3. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017;5:691-706.
4. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom 2018;3:24.
5. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013;5:235-245.
6. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract 2013;21.
7. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
8. Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res 2020;6:00325-2019.
9. Sprooten RT, Rohde GG, Lawyer G, Leijte WT, Wouters EF, Franssen FM. Risk stratification for short-term mortality at hospital admission for acute exacerbations of COPD. Respir Med 2019;147:76-776.
10. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;42:812-818.
11. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol 2019;144:1-12.
12. Agusti A, Celli B, Faner R. What does endotyping mean for treatment in chronic obstructive pulmonary disease? Lancet 2017;390:986-987.
13. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-1700.
14. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;183:562-567.
15. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am J Respir Crit Care Med 2016;193:965-974.
16. Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosino-
17. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018;6:117-126.
18. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018;52:180219.
19. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017;377:1612-1620.
20. Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med 2019;381:117-126.
21. Eosinophils and exacerbation risk in patients with COPD. Eur Respir J 2017;50:1700761.
22. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018;6:117-126.
23. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018;52:180219.
24. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017;377:1613-1620.
25. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res 2010;2:87-101.
26. Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm 2015;2015:879783.
27. McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne) 2017;4:93.
28. Van Hulst G, Batugedara HM, Jorssen J, Louis R, Bureau F, Desmet CJ. Eosinophil diversity in asthma. Biochem Pharmacol 2020;179:113963.
29. Amin K, Janson C, Bystrom J. Role of eosinophil granulocytes in allergic airway inflammation endotypes. Scand J Immunol 2016;84:75-85.
30. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 2018;128:997-1009.
31. Flores-Torres AS, Salinas-Carmona MC, Salinas E, Rosas-Taraco AG. Eosinophils and respiratory viruses. Viral Immunol 2019;33:198-207.
32. Arora S, Ahmad S, Ishad R, et al. TLRs in pulmonary diseases. Life Sci 2019;233:116671.
33. Nakagome K, Nagata M. Involvement and possible role of eosinophils in asthma exacerbation. Front Immunol 2018;9:2220.
34. Pelaia G, Vatrella A, Busceti MT, et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther 2017;11:3137-3144.
35. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.
36. Haldar P, Brightling CE, Hargaden B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
37. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:290-300.
38. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-2141.
39. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-2127.
40. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376:2448-2458.
41. Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med 2017;196:1385-1395.
42. Lin A, Lore K. Granulocytes: new members of the antigen-presenting cell family. Front Immunol 2017;8:1781.
43. Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J 2019;53:180219.
44. Daud R, al Kawtly K, Al-Zain A. Elevated serum of ECP in acute exacerbations of COPD. J Chem Pharm Res 2015;7:401-406.
45. Isobe Y, Kato T, Arita M. Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol 2012;3:270.
46. Global Initiative for Asthma. Global strategy for asthma management and prevention 2020 [Internet]. Fontana (WI): GINA, 2021 [cited 2021 Sep 14]. Available from: https://ginasthma.org/.
43. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-1485.
44. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
45. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:190-208.
46. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998;158(5 Pt 2):S53-S57.
47. Hargreave FE, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160(5 Pt 2):1511-1517.
48. Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017;5:966-967.
49. Lim HF, Nair P. The evolution of sputum cytometry to assess bronchitis. Can Respir J 2013;20:415-416.
50. Gao P, Gibson PG, Zhang J, et al. The safety of sputum induction in adults with acute exacerbation of COPD. Clin Respir J 2013;7:101-109.
51. Lim HF, Nair P. Airway inflammation and inflammatory biomarkers. Semin Respir Crit Care Med 2018;39:1-10.
52. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med 2002;95:999-1002.
53. Beeh KM, Beier J, Kornmann O, Mander A, Buhl R. Long-term repeatability of induced sputum cells with clinical inflammatory markers in stable, moderately severe COPD. Chest 2003;123:778-783.
54. Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol 2017;140:1181-1184.
55. Schleich F, Corhay JL, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J 2016;47:1562-1564.
56. Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1405-1504.
57. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarnic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2018;389:1076-1084.
58. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRIOLOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;389:97-107.
59. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747-758.
60. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;379:1671-1680.
61. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020;382:33-43.
62. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-398.
63. Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:329-339.
64. Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk: maybe just for some? Am J Respir Crit Care Med 2016;193:397-407.
67. Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019;7:745-756.

68. Oshagbemi OA, Burden AM, Braeken DC, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med 2017;195:1402-1404.

69. Schumann DM, Tamm M, Kostikas K, Stolz D. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest 2019;156:456-465.

70. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation 2013;36:1178-1185.

71. Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, Dehghan A, Bourbeau J. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review. COPD 2018;13:377-391.

72. Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J 2018;51:1702536.

73. Ko FW, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology 2020;25:259-266.

74. Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017;50:1701162.

75. MacDonald MI, Osadnik CR, Bullfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest 2019;156:92-100.

76. Vedel-Krogh S, Nordestgaard BG, Lange P, Vestbo J, Nielsen SF. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. Eur Respir J 2018;52:1801210.

77. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016;4:731-741.

78. Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD: relationship with bacterial load. Respir Res 2017;18:88.

79. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD [Internet]. Fontana (WI): GOLD, 2021 [cited 2021 Sep 14]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.

80. Papi A, Kostikas K, Wedzicha JA, et al. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med 2018;197:1223-1226.

81. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-442.

82. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-1036.

83. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953.

84. Loppow D, Schleiss MB, Kanniess F, Taube C, Jonges RA, Magnusen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001;95:121-125.

85. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2012;7:597-595.

86. Tsang KW, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-727.

87. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55.

88. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-1947.

89. Tantucci C, Pini L. Inhaled corticosteroids in COPD: trying to make a long story short. Int J Chron Obstruct
90. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-735.
91. de Marco R, Marcon A, Rossi A, et al. Asthma, COPD and overlap syndrome: a longitudinal study in young European adults. Eur Respir J 2015;46:671-679.
92. Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015;135:63-72.
93. Hirai K, Shirai T, Suzuki M, et al. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin Exp Allergy 2017;47:1374-1382.
94. Rootmensen G, van Keimpema A, Zwinderman A, Sterk P. Clinical phenotypes of obstructive airway diseases in an outpatient population. J Asthma 2016;53:1026-1032.
95. Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, COPD and asthma-COPD overlap. Respirology 2021;26:52-61.
96. Kostikas K, Clemens A, Patalano F. The asthma-COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease? Int J Chron Obstruct Pulmon Dis 2016;11:1297-1306.
97. Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi SM, et al. Identification and definition of asthma-COPD overlap: the CanCOLD study. Respirology 2020;25:836-849.
98. Lange P, Colak Y, Ingebrigtsen TS, Vestbo J, Marott JL. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med 2016;4:454-462.